Drug Trial Radar · NCT01471340
A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)
Last checked: Nov 19, 2026Latest source record: May 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11,744
Actual
Start
Jan 9, 2012
Primary completion
Nov 30, 2016
Study completion Nov 30, 2016
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Nov 16, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the safety of DULERA. DULERA is a pressurized metered-dose inhaler (MDI) that contains two drugs combined, namely mometasone and formoterol in a single inhaler. Mometasone is an inhaled corticosteroid (ICS), which reduces the inflammation in the airways. Formoterol is a long-acting beta 2 agonist (LABA), which helps to relax the muscles of the airways in the lungs, making it easier to breathe. In combination, mometasone and formoterol are used for the treatment of asthma. This study will evaluate whether participants taking a LABA in combination with an ICS in a single inhaler have a different risk of having serious asthma events (hospitalization, intubation and death) compared to participants taking an ICS alone. The primary safety hypothesis is that the time-to-first serious asthma outcome (SAO) with mometasone furoate/formoterol (MF/F) MDI twice daily (BID) is non-inferior to that with mometasone furoate (MF) MDI BID in adolescents and adults with persistent asthma. If non-inferiority is achieved, the key secondary safety hypothesis of superiority of MF/F over MF will be assessed.
Conditions
- Asthma
Interventions
Mometasone Furoate/Formoterol MDI 100/5 mcgDrug
two inhalations BID
Mometasone Furoate/Formoterol MDI 200/5 mcgDrug
two inhalations BID
Mometasone Furoate MDI 100 mcgDrug
two inhalations BID
Mometasone Furoate MDI 200 mcgDrug
two inhalations BID
Albuterol 90 mcg /salbutamol 100 mcg HFA MDIDrug
use as needed for asthma symptoms
Prednisone/prednisoloneDrug
Oral prednisone/prednisolone used only as an emergency rescue medication at the discretion of the investigator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-to-First Serious Asthma Outcomes (SAO): Number of First SAO in the MF/F vs MF ArmsTime frame: 26 weeks, or 7 days after the last treatment dose, whichever occurred later
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.